John Reeves Written submissions should be addressed to the Secretary, Joint Committee on the Legalisation of Medicinal Cannabis, and emailed to JCLMC@parliament.sa.gov.au or posted to GPO Box 572, Adelaide SA 5001.

Medicinal Cannabis has been proven to have amazing therapeutic benefits and this realisation is creating immense demand for Cannabis that is high quality, consistent and has a diversity of genetics.

15/03/2023 Submission to the Joint Committee on the Legalisation of Medicinal Cannabis Dear Members of the Joint Committee on the Legalisation of Medicinal Cannabis, I write to you as a person who is currently accessing Medicinal Cannabis, prescribed by a General Practitioner, under the Therapeutic Goods Administration Special Access Scheme and Authorised Provider pathway.

The first is Section 3.8.1 on Barriers to accessing medicinal cannabis: The burden of drug testing on medicinal cannabis patients (pp. 61-64).

Submission to Parliamentary Committee Medicinal Cannabis Legislation To whom it may concern My name is and I am a Medicinal Cannabis user.

https://nadk.flinders.edu.au/kb/cannabis/cannabis-health/what-are- the-physical-health-risks-of-using-cannabis 7.

To the Members of the Joint Commi ee on the Legisla on of Medicinal Cannabis, My name is Katherine Cooper, I live in Mount Gambier South Australia.

- The role of medicinal cannabis as a treatment for endometriosis and law reforms needed to remove barriers in accessing medicinal cannabis

Studies on the Reliability of THC as a Biomarker of Impairment in Cannabis Users: Introduction: THC (delta-9-tetrahydrocannabinol) is the main psychoactive compound found in cannabis, and it is the primary target for drug testing in order to determine impairment in cannabis users.